FR2796643B1 - Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique - Google Patents

Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

Info

Publication number
FR2796643B1
FR2796643B1 FR9909496A FR9909496A FR2796643B1 FR 2796643 B1 FR2796643 B1 FR 2796643B1 FR 9909496 A FR9909496 A FR 9909496A FR 9909496 A FR9909496 A FR 9909496A FR 2796643 B1 FR2796643 B1 FR 2796643B1
Authority
FR
France
Prior art keywords
dihydrothiazoles
arylimino
derivatives
processes
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9909496A
Other languages
English (en)
Other versions
FR2796643A1 (fr
Inventor
Christophe Moinet
Carole Sackur
Christophe Thurieau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to FR9909496A priority Critical patent/FR2796643B1/fr
Priority to ARP000103722A priority patent/AR035321A1/es
Priority to MXPA02000723A priority patent/MXPA02000723A/es
Priority to NZ516599A priority patent/NZ516599A/xx
Priority to CNB008107157A priority patent/CN100443479C/zh
Priority to PCT/FR2000/002095 priority patent/WO2001007424A1/fr
Priority to US10/031,429 priority patent/US6727269B1/en
Priority to CZ20020187A priority patent/CZ302073B6/cs
Priority to BR0012647-0A priority patent/BR0012647A/pt
Priority to AU70053/00A priority patent/AU782187B2/en
Priority to KR1020027000839A priority patent/KR100692352B1/ko
Priority to PL00353831A priority patent/PL353831A1/xx
Priority to JP2001512509A priority patent/JP4063537B2/ja
Priority to EP00958575A priority patent/EP1202980A1/fr
Priority to HU0202425A priority patent/HUP0202425A3/hu
Priority to CA2382940A priority patent/CA2382940C/fr
Priority to RU2002104574/04A priority patent/RU2266287C2/ru
Priority to IL14758200A priority patent/IL147582A0/xx
Publication of FR2796643A1 publication Critical patent/FR2796643A1/fr
Priority to IL147582A priority patent/IL147582A/en
Priority to NO20020314A priority patent/NO322394B1/no
Priority to HK03100526.0A priority patent/HK1048314A1/xx
Priority to US10/615,481 priority patent/US7220765B2/en
Application granted granted Critical
Publication of FR2796643B1 publication Critical patent/FR2796643B1/fr
Priority to JP2006114071A priority patent/JP2006257093A/ja
Priority to IL185786A priority patent/IL185786A0/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
FR9909496A 1999-07-22 1999-07-22 Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique Expired - Fee Related FR2796643B1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FR9909496A FR2796643B1 (fr) 1999-07-22 1999-07-22 Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
ARP000103722A AR035321A1 (es) 1999-07-22 2000-07-19 Derivados de 2-arilimino-2,3-dihidrotiazoles, procedimiento para su preparacion, y uso de los mismos para preparar medicamentos y composiciones farmaceuticas
CA2382940A CA2382940C (fr) 1999-07-22 2000-07-21 2-arylimino-2,3-dihydrothiazoles et leur utilisation comme ligands des recepteurs de la somatostatine
CNB008107157A CN100443479C (zh) 1999-07-22 2000-07-21 2-芳基亚氨基-2,3-二氢噻唑和它们作为生长激素释放抑制因子受体配体的用途
PCT/FR2000/002095 WO2001007424A1 (fr) 1999-07-22 2000-07-21 2-arylimino-2,3-dihydrothiazoles et leur utilisation comme ligands des recepteurs de la somatostatine
US10/031,429 US6727269B1 (en) 1999-07-22 2000-07-21 2-Arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
CZ20020187A CZ302073B6 (cs) 1999-07-22 2000-07-21 2-Arylimino-2,3-dihydrothiazoly a jejich použití jako ligandu somatostatinových receptoru
BR0012647-0A BR0012647A (pt) 1999-07-22 2000-07-21 Composto, processo de preparação do mesmo, produto, composição farmacêutica, e utilização do produto
AU70053/00A AU782187B2 (en) 1999-07-22 2000-07-21 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
KR1020027000839A KR100692352B1 (ko) 1999-07-22 2000-07-21 2-아릴이미노-2,3-디히드로티아졸 및 그의 소마토스타틴수용체 리간드로서의 용도
PL00353831A PL353831A1 (en) 1999-07-22 2000-07-21 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
JP2001512509A JP4063537B2 (ja) 1999-07-22 2000-07-21 ２−アリールイミノ−２，３−ジヒドロチアゾール類及びそのソマトスタチンレセプターのリガンドとしての使用
MXPA02000723A MXPA02000723A (es) 1999-07-22 2000-07-21 2-arilimino-2,3-dihidrotiazoles y su uso como ligandos de receptores de somatostatina.
HU0202425A HUP0202425A3 (en) 1999-07-22 2000-07-21 2-arylimino-2,3-dihydrothiazoles, their preparation and use thereof as somatostatin receptor ligands
NZ516599A NZ516599A (en) 1999-07-22 2000-07-21 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
RU2002104574/04A RU2266287C2 (ru) 1999-07-22 2000-07-21 2-арилимино-2,3-дигидротиазолы, способы их получения и фармацевтическая композиция, их содержащая
IL14758200A IL147582A0 (en) 1999-07-22 2000-07-21 2-arylimino-2, 3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
EP00958575A EP1202980A1 (fr) 1999-07-22 2000-07-21 2-arylimino-2,3-dihydrothiazoles et leur utilisation comme ligands des recepteurs de la somatostatine
IL147582A IL147582A (en) 1999-07-22 2002-01-10 2 - Arylamino - 2,3 - Dihydrotiazoles, their preparation, their use in the preparation of medicinal preparations, and medicinal preparations containing them
NO20020314A NO322394B1 (no) 1999-07-22 2002-01-21 2-arylimino-2,3-dihydrotiazoler, fremgangsmate for fremstilling av disse, farmasoytiske preparater inneholdende disse samt deres anvendelse for fremstilling av medikamenter for behandling av tilstander eller sykdommer der somatostatinreseptorene er innvolvert.
HK03100526.0A HK1048314A1 (en) 1999-07-22 2003-01-22 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
US10/615,481 US7220765B2 (en) 1999-07-22 2003-07-08 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use
JP2006114071A JP2006257093A (ja) 1999-07-22 2006-04-18 ２−アリールイミノ−２，３−ジヒドロチアゾール類及びそのソマトスタチンレセプターのリガンドとしての使用
IL185786A IL185786A0 (en) 1999-07-22 2007-09-06 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9909496A FR2796643B1 (fr) 1999-07-22 1999-07-22 Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

Publications (2)

Publication Number Publication Date
FR2796643A1 FR2796643A1 (fr) 2001-01-26
FR2796643B1 true FR2796643B1 (fr) 2005-04-29

Family

ID=9548380

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9909496A Expired - Fee Related FR2796643B1 (fr) 1999-07-22 1999-07-22 Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

Country Status (20)

Country Link
US (1) US6727269B1 (fr)
EP (1) EP1202980A1 (fr)
JP (2) JP4063537B2 (fr)
KR (1) KR100692352B1 (fr)
CN (1) CN100443479C (fr)
AR (1) AR035321A1 (fr)
AU (1) AU782187B2 (fr)
BR (1) BR0012647A (fr)
CA (1) CA2382940C (fr)
CZ (1) CZ302073B6 (fr)
FR (1) FR2796643B1 (fr)
HK (1) HK1048314A1 (fr)
HU (1) HUP0202425A3 (fr)
IL (3) IL147582A0 (fr)
MX (1) MXPA02000723A (fr)
NO (1) NO322394B1 (fr)
NZ (1) NZ516599A (fr)
PL (1) PL353831A1 (fr)
RU (1) RU2266287C2 (fr)
WO (1) WO2001007424A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2819508B1 (fr) * 2001-01-12 2005-01-21 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques
ATE451102T1 (de) * 2000-06-30 2009-12-15 Dainippon Sumitomo Pharma Co Thiazol-derivate zur verwendung als entzündungshemmende mittel
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
WO2003057214A1 (fr) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Derives d'hydantoine presentant une affinite pour les recepteurs de la somatostatine
US7067538B2 (en) 2002-08-09 2006-06-27 Warner-Lambert Company, Llc MCP-1 receptor antagonists and methods of use thereof
JP4896387B2 (ja) * 2003-09-30 2012-03-14 武田薬品工業株式会社 チアゾリン誘導体およびその用途
EP1669352A4 (fr) 2003-09-30 2008-12-17 Takeda Pharmaceutical Derive thiazoline et utilisation
WO2005082845A1 (fr) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Nouvelles therapies a base d'agonistes du recepteur de la somatostatine
WO2005082844A1 (fr) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Traitement de maladies au moyen d'un agoniste de recepteurs de somatostatine
PL2653465T3 (pl) 2004-03-15 2017-01-31 Janssen Pharmaceutica Nv Modulatory receptora opioidowego
AU2012202459B2 (en) * 2004-03-15 2014-06-12 Janssen Pharmaceutica, N.V. Novel compounds as opioid receptor modulators
US7910613B2 (en) * 2004-09-22 2011-03-22 H. Lundbeck A/S 2-acylaminothiazole derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
EP2024349B1 (fr) 2006-05-31 2017-08-02 AbbVie Inc. Composés constituant des ligands de récepteurs cannabinoïdes et utilisations de ces composés
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
BRPI0712720A2 (pt) * 2006-05-31 2012-11-20 Abbott Lab compostos tiazàis como ligantes do receptor canabinàide e usos dos mesmos
WO2008028094A1 (fr) 2006-08-31 2008-03-06 Abbott Laboratories Composés utilisés en tant que ligands de récepteurs cannabinoides cb2
US7868038B2 (en) 2006-08-31 2011-01-11 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2142522A1 (fr) 2007-03-28 2010-01-13 Abbott Laboratories Composés 1,3-thiazol-2(3h)-ylidene en tant que ligands de récepteur cannabinoïde
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
CN101711253A (zh) 2007-05-18 2010-05-19 雅培制药有限公司 用作大麻素受体配体的新化合物
KR100863239B1 (ko) 2007-05-23 2008-10-15 한국과학기술연구원 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
JP2011513495A (ja) 2008-03-11 2011-04-28 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての新規な化合物
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2737199A1 (fr) 2008-09-16 2010-03-25 Abbott Laboratories Composes inedits utilisables en tant que ligands des recepteurs cannabinoides
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
KR101856266B1 (ko) 2010-08-09 2018-05-09 가부시키가이샤 에누비 켄코우겡큐쇼 카세인 키나아제 1δ 및 카세인 키나아제 1ε 저해제
WO2021005081A1 (fr) * 2019-07-10 2021-01-14 Bayer Aktiengesellschaft Procédé de fabrication de 2-(phénylimino)-1,3-thiazolidine-4-ones
US20220251053A1 (en) * 2019-07-10 2022-08-11 Bayer Aktiengesellschaft Process of preparing 2-(phenylimino)-1,3-thiazolidin-4-ones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345257A (en) * 1962-01-19 1967-10-03 Ciba Ltd Method for combatting microorganisms
US3264316A (en) * 1963-09-18 1966-08-02 Res Lab Dr C Janssen N V Certain 2-acylimino-3-substitutedthiazoline-4 compounds
DE2926771A1 (de) * 1979-07-03 1981-01-15 Hoechst Ag Thiazolidinderivate und verfahren zu ihrer herstellung
DE3049460A1 (de) * 1980-12-30 1982-07-29 Hoechst Ag, 6000 Frankfurt "thiazolinderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
US5521145A (en) * 1994-04-04 1996-05-28 Sumitomo Chemical Company, Ltd. Iminothiazoline derivatives and herbicides containing them as active ingredients
JPH07324079A (ja) * 1994-04-04 1995-12-12 Sumitomo Chem Co Ltd イミノチアゾリン誘導体およびその用途
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
IL185786A0 (en) 2008-01-06
JP2003505453A (ja) 2003-02-12
CA2382940C (fr) 2010-08-17
HUP0202425A2 (en) 2002-10-28
CZ302073B6 (cs) 2010-09-29
NO20020314D0 (no) 2002-01-21
WO2001007424A1 (fr) 2001-02-01
US6727269B1 (en) 2004-04-27
HK1048314A1 (en) 2003-03-28
BR0012647A (pt) 2002-04-09
CN100443479C (zh) 2008-12-17
AU782187B2 (en) 2005-07-07
JP2006257093A (ja) 2006-09-28
CN1362952A (zh) 2002-08-07
FR2796643A1 (fr) 2001-01-26
CA2382940A1 (fr) 2001-02-01
JP4063537B2 (ja) 2008-03-19
KR20020088405A (ko) 2002-11-27
KR100692352B1 (ko) 2007-03-12
AR035321A1 (es) 2004-05-12
HUP0202425A3 (en) 2002-12-28
RU2002104574A (ru) 2004-01-20
IL147582A (en) 2009-08-03
MXPA02000723A (es) 2002-09-17
EP1202980A1 (fr) 2002-05-08
NO20020314L (no) 2002-03-06
PL353831A1 (en) 2003-12-01
CZ2002187A3 (cs) 2002-06-12
RU2266287C2 (ru) 2005-12-20
AU7005300A (en) 2001-02-13
NZ516599A (en) 2004-01-30
IL147582A0 (en) 2002-08-14
NO322394B1 (no) 2006-10-02

Similar Documents

Publication Publication Date Title
FR2796643B1 (fr) Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
FR2791678B1 (fr) Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
NO20021400D0 (no) Terapeutiske konazolinderivater
NO20014013L (no) 16-halogen-epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem
FR2790474B1 (fr) Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2843964B1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
MA27233A1 (fr) Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique
NO20005179D0 (no) Medikament behandling
FR2809731B1 (fr) Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
FR2809730B1 (fr) Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique
EE200100422A (et) Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
FR2819508B1 (fr) Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques
FR2845388B1 (fr) Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
FR2792318B1 (fr) Derives d'indazole, leur preparation et leur application en therapeutique
FR2751647B1 (fr) Derives de benzimidazole, leurs preparations et leurs applications en therapeutique
NO20016430L (no) Farmasöytisk kompleks
FR2765874B1 (fr) Derives de 6-pyrrolidin-2-ylpyrindines, leur preparation et leur application en therapeutique
EE200100579A (et) 6-[(arüül- ja heteroarüül)oksü]metüül]naftaleen-2-karboksimiidamiidi derivaadid, nende valmistamineja nende terapeutiline kasutamine
FR2792635B1 (fr) Derives de cyclobutene-3,4-dione leur preparation et leur application en therapeutique
FR2724382B1 (fr) Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique
FR2805815B1 (fr) Derives de polyfluoroalkylimidazole, leur preparation et leur application en therapeutique
FR2816619B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2792634B1 (fr) Derives de 2-alcoxy-cyclobutene-3,4-dione leur preparation et leur application en therapeutique
FR2783521B1 (fr) Derives de n-(arginyl) benzenesulfonamide, leur preparation et leur application en therapeutique
FR2773800B1 (fr) Derives de benzimidazole, leur procede de preparation et leur application en therapeutique

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
ST Notification of lapse

Effective date: 20120330